These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease.
    Author: Rudra S, Shaul E, Conrad M, Patel T, Moore A, Dawany N, Canavan MC, Sullivan KE, Behrens E, Kelsen JR.
    Journal: Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1408-1410.e2. PubMed ID: 34329777.
    Abstract:
    Very early onset inflammatory bowel disease (VEO-IBD), diagnosed <6 years old, can be genetically and phenotypically distinct and more refractory than older-onset IBD. Identified causal monogenic defects have been targeted therapeutically in a small subset of VEO-IBD1; however, for most of these children, treatment strategies, such as phenotypic profiles, are critically needed to improve outcomes.
    [Abstract] [Full Text] [Related] [New Search]